VERU INC. Equity Securities, FV-NI, Unrealized Gain (Loss)
VERU INC. (VERU) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $108.74 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-10
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $108.74K.
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was $1.98M.
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was -$120.08K.
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was -$323.77K, a 163.06% decline year-over-year.
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$323.77K.
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was -$176.08K.
- VERU INC. equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $0.00.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month as first filed | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $108.74K 10-Q · filed 2026-08-10 | $2.09M derived: sum of 2 quarters · filed 2026-08-10 | $1.15M 10-Q · filed 2026-08-10 | $1.64M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2026-03-31 | $1.98M 10-Q · filed 2026-05-13 | $1.73M 10-Q · filed 2026-05-13 | $1.53M derived: sum of 3 quarters · filed 2026-05-13 | $1.53M derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-12-31 | -$120.08K 10-Q · filed 2026-02-11 | -$443.85K derived: sum of 2 quarters · filed 2026-02-11 | -$443.85K derived: sum of 3 quarters · filed 2026-08-10 | -$443.85K derived: sum of 4 quarters · filed 2026-08-10 | ||
| 2025-09-30 | -$323.77K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | -$323.77K derived: sum of 2 quarters · filed 2026-08-10 | -$323.77K derived: sum of 3 quarters · filed 2026-08-10 | -$323.77K 10-K · filed 2025-12-17 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $0.00 10-Q · filed 2026-08-10 | -$349.08K 10-Q · filed 2025-08-12 | $164.39K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | -$349.08K 10-Q · filed 2025-05-08 | $164.39K derived: sum of 3 quarters · filed 2026-05-13 | $46.77K derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$349.08K 10-Q · filed 2026-02-11 | $164.39K derived: sum of 2 quarters · filed 2026-02-11 | $46.77K derived: sum of 3 quarters · filed 2026-02-11 | -$145.26K derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-09-30 | $513.47K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-17 | $395.85K derived: sum of 2 quarters · filed 2025-12-17 | $203.82K derived: sum of 3 quarters · filed 2025-12-17 | -$176.08K 10-K · filed 2025-12-17 | ||
| 2024-06-30 | -$117.62K 10-Q · filed 2025-08-12 | -$309.65K derived: sum of 2 quarters · filed 2025-08-12 | -$689.55K 10-Q · filed 2025-08-12 | -$689.55K derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | -$192.03K 10-Q · filed 2025-05-08 | -$571.93K 10-Q · filed 2025-05-08 | -$571.93K derived: sum of 3 quarters · filed 2025-05-08 | -$571.93K derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$379.90K 10-Q · filed 2025-02-13 | -$379.90K derived: sum of 2 quarters · filed 2025-02-13 | -$379.90K derived: sum of 3 quarters · filed 2025-02-13 | |||
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-16 | $0.00 derived: sum of 2 quarters · filed 2024-12-16 | $0.00 10-K · filed 2024-12-16 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |